Em­bold­ened by Dupix­ent COPD win, Sanofi ex­ecs pitch lead­ing im­munol­o­gy's next era

Since launch­ing in 2017, Dupix­ent has racked up a range of ap­provals on its path to be­com­ing Sanofi’s best-sell­ing drug.

On Sun­day, Sanofi and Re­gen­eron high­light­ed an­oth­er late-stage Dupix­ent suc­cess that could make it the first bi­o­log­ic med­i­cine to treat COPD, or chron­ic ob­struc­tive pul­monary dis­ease. Re­sults were pub­lished in The New Eng­land Jour­nal of Med­i­cine and pre­sent­ed at the Amer­i­can Tho­racic So­ci­ety’s meet­ing in Wash­ing­ton.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.